Dear Sir, With interest we read the study by Cho et al [1] , evaluating the usefulness of FDG PET/CT for differentiating malignant endobronchial lesions with distal atelectasis from benign bronchial stenosis. In this retrospective study, they adequately demonstrated the additional value of FDG PET/ CT in this challenging clinical problem. Besides differentiation of endobronchial lesions, accurate discrimination between malignant tumours and atelectatic lung tissue can facilitate the definition of radiotherapy target volumes. As a result, the size of radiotherapy fields can be decreased [2] , potentially reducing radiotherapy-induced side-effects.
For these purposes, the PET technique may be of additional value to discriminate the obstructive lesion from the atelectatic lung tissue. Although Cho et al [1] mentioned different patterns of FDG uptake in atelectatic lung tissue, we wonder whether the FDG uptake in the obstructive lesions could be adequately distinguished from the FDG uptake in the atelectatic lung tissue. As FDG uptake is dependent on perfusion for its delivery to tissue, variation in tissue vascularity may contribute to variable FDG uptake in obstructive atelectasis. In a previous PET/ CT study, we quantified tumour perfusion in lung cancer patients using radiolabelled water ([ 15 O]H 2 O) [3] . The measured perfusion values in atelectatic lung tissue differed significantly as compared with perfusion values in malignant tumours. Figure 1 shows an example of a patient with relatively high perfusion in atelectatic lung tissue as compared with the malignant tumour. These observations suggest that perfusion measurements may have additional value to discriminate atelectatic lung tissue from malignant lesions. Therefore, we believe that additional perfusion measurements of atelectatic lung tissue may improve diagnosis and radiotherapy planning of malignant endobronchial lesions. 
